Kartik Anand

Son,Husband,Father of Twins and Medical Oncologist in Midwest U.S.

[Bloodbytes @DrSwami_Iyer]

@BLLPHD @NitinJainMD @KAnandMD @PatrickHwuMD @tcellsrus @RaviPingali1 We trace the CHIP clone from the lung biopsy that eventually becomes the predominant TCL clone.

[Bloodbytes @DrSwami_Iyer]

@BLLPHD @NitinJainMD Very similar to our report in 2020 post Pembrolizumab due to PD1 blockade in a TET2 CHIP and PD1 haploinsufficiency. https://t.co/iDkXASnCwu @KAnandMD @PatrickHwuMD @tcellsrus @RaviPingali1

[Kartik Anand @KAnandMD]

@UNMC_IM @UNMCHemeOnc @unmc_research Congratulations Dr. Bhatt.

[JIPO Editors @JIPOEditors]

This new research article in #JIPO by Ebinama et al. discusses pulmonary immune-related adverse events of PD1 versus PDL-1 checkpoint Inhibitors
https://t.co/yiWWdcEEO0
#ROR #AdverseEvents
@UgochiEbinama @ajaysheshadri @KAnandMD @ANaingMD

[Eric Bernicker MD FASCO @EricBernicker]

Proud of the work our team led by Dr Ethan Burns did looking at the NCDB ; octogenarians with lung cancer did significantly better with IO however significant disparities exist; much work still to be done, #LungCancer https://t.co/9sbfCjBq2z

[JIPO Editors @JIPOEditors]

This new research article in #JIPO by Ebinama et al. discusses pulmonary immune-related adverse events of PD1 versus PDL-1 checkpoint Inhibitors
https://t.co/yiWWdcEEO0
#ROR #AdverseEvents
@UgochiEbinama @ajaysheshadri @KAnandMD @ANaingMD

[JIPO Editors @JIPOEditors]

This new research article in #JIPO by Ebinama et al. discusses pulmonary immune-related adverse events of PD1 versus PDL-1 checkpoint Inhibitors
https://t.co/yiWWdcEEO0
#ROR #AdverseEvents
@UgochiEbinama @ajaysheshadri @KAnandMD @ANaingMD

[sganguly @bmtdoc63]

CMV and Transplant. CMV memory resides in donor lymphocytes.
CMV IGG status and risk
D-/R-: Negligible chance of transmission
D+/R-: Transmitting CMV memory from D to R. Not bad
D+/R+: Could lead to reactivation
D-/R+: Worst. Last two should get prophylaxis with Letermovir.

[Kartik Anand @KAnandMD]

Pulmonary irAEs more with PD-1 inhibitors compared to PD-L1 inhibitors. @UgochiEbinama @DrSwami_Iyer
https://t.co/FZTglc6HI7

[Anthony Pompliano 🌪 @APompliano]

Wow!

A witness just testified in front of Congress that the government has recovered “non-human” pilots from UFOs.

What. A. Time. To. Be. Alive. https://t.co/dWydIrRBYb

[Vincent Rajkumar @VincentRK]

Myeloma drugs — Dosing and schedule

What I do in practice #MedTwitter

1. Dex: 40 mg once a week age <70; 20 mg if age >70 or frail

Stop Dex at around one year if good response.

Days 1-4, 8, 15, 22 schedule for 1st cycle only in cast nephropathy; or VDT-PACE type regimen

[Kartik Anand @KAnandMD]

@VivekSubbiah So clonal hematopoiesis protective for AD but increases risk of CAD.

[Jordan Schneider @jordanschneider]

OpenAI's newly released Code Interpreter changes everything.

Every business on the planet now has access to an on-demand team of McKinsey consultants for $20/month.

To see why, here's what I was able to do in 10 minutes with my own company's data:

[Sahil Bloom @SahilBloom]

This Reddit post hit me hard.

[Rowan Cheung @rowancheung]

You need to stop manually making presentations.

This AI tool is ChatGPT for your slide decks.

Here's how to use it to save hours of work (completely free):

[NEJM @NEJM]

A phase 3 trial of BCMA-specific CAR T cells in relapsed and refractory myeloma showed an advantage over standard therapy (progression-free survival, 13.3 vs. 4.4 months); 39% of patients in the ide-cel group had a complete response. https://t.co/i0BaknXtNB

#CART23

[Jenny C. Chang @JennyCChang1]

#tnbc #MpBC #Bcsm Just opened phase 1/2 study for orphan and lethal metastatic Metaplastic breast cancer. Supported by NCI U01, pts receive drugs that block the two oncogenic drivers of this rare disease - PI3K & iNOS (LNMMA). Preclinical data stunning. All referrals please

[Kartik Anand @KAnandMD]

@Geeky_Foodie Sorry to hear this.

[Benlazar S M A @smbenlazar]

Navigating the Evolving Treatment Landscape of Diffuse Large B-Cell Lymphoma https://t.co/QzGrwz8v80 #DLBCL #lysm

[Kartik Anand @KAnandMD]

@VijayaRBhatt1 @UNMCHemeOnc Congratulations!